nejm semaglutide ckd Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – SOUL Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 Semaglutide in patients with overweight

In theory, this could pave the way for even greater efficacy for GLP-1 treatments while also achieving an important reduction in the currently high rate of adverse GI events

Start your intake Why Stopping GLP-1 Medication Cold Turkey Backfires GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone that signals satiety and slows gastric emptying

Reta: Enhanced Energy Metabolism The inclusion of glucagon receptor activity sets Reta apart

Working with the students is especially rewarding

Researchers using a 5-day-on, 2-day-off cycling protocol report more consistent onset windows than those using KLOW daily without breaks